TSX:PLC - Post Discussion
Post by
retiredcf on Mar 04, 2022 8:43am
TD
This is a flash report and their current target is $47.00. GLTA
Park Lawn Corp.
(PLC-T) C$33.88
First Look: In Line Q4; Robust New Five-year Growth Target Provided
Event
-
PLC reported Q4/21 adjusted EBITDA of $25.2mm (up 4.0% y/y), in line with our estimate/consensus of $25.0mm/$25.5mm. Both margins and revenues were in line. The company also provided effectively in line 2022 guidance and a new five- year aspirational growth target for US$150mm of EBITDA in 2026 (implies ~15% CAGR, assuming 2021 baseline).
-
CC: 9:30 a.m. ET (888-506-0062; code: 490276).
Impact: SLIGHTLY POSITIVE
-
Consolidated Q4/21 net revenue increased 10.1% y/y to $99.5mm, driven almost entirely by acquisitions. Organic growth (ex. F/X) of 0.7% was slightly above our estimate of -2.0%, with the y/y decline in COVID-19-related deaths more than offset by higher average revenue per call (due to relaxed social distancing requirements and expanded services offering) and continued strong pre-need sales with COVID-19 continuing to act as a triggering event for individuals to evaluate post death alternatives.
-
Adjusted EBITDA margin of 25.3% was effectively in line (TD: 25.5%). We continue to believe that further margin expansion is possible as synergies are realized from recent acquisitions.
-
Balance sheet: As at Q4/21, the leverage ratio was 0.98x (1.78x inclusive of debentures) and PLC had ~$215mm of available liquidity (cash plus revolver).
-
Guidance: Management expects to modestly exceed its 2018 aspirational growth target of C$100mm (US$79mm) of adjusted EBITDA in 2022, before considering the impact of any potential future acquisitions. We view this as largely in line with our current 2022 estimate of $109mm (cons: $115mm, but some analysts forecast unannounced acquisitions). PLC also set a new 2026 aspirational target of US $150mm of adjusted EBITDA and adjusted net earnings exceeding US$2.00/sh.
-
In our view, the 2022 guidance and 2026 target should ease investor concerns related to a possible softening of near-term results due to a potential pull-forward impact related to the elevated COVID-19 related death rates in 2020/2021. Furthermore, we would highlight recent commentary from U.S. life insurance companies which have cited expectations for elevated non- COVID-19-related deaths in 2022 and beyond (i.e above 2019 levels), reflecting deferral of medical care during the pandemic, possible future complications from COVID-19 infection and societal-related issues including increased prevalence of substance abuse, among other factors.
Be the first to comment on this post